Pfizer Stock News

There are some stocks to make friends envious for March this year. These companies have impressive growth prospects and strong fundamentals that position them for potential outperformance.

Pfizer would need to generate exceptional growth to reach a market cap of $1 trillion by 2035. Several obstacles could make achieving this goal difficult.

The financial landscape is a dynamic arena with opportunities for the astute investor keen on solving its complexities. Within this broad spectrum of investment choices, entities exist that shine as i

Pfizer's stock is paying a dividend that yields more than four times the S&P 500 average. It had a tough 2023, but if not for asset impairment charges, results would have looked far better.

Pfizer (PFE) closed at $27.63 in the latest trading session, marking a -0.32% move from the prior day.

Dividend stocks are looking more and more attractive these days. Especially when you consider a given share of some companies can be prohibitively expensive.

Pfizer (PFE) plans to sell some shares of consumer healthcare firm Haleon (HLN), which it owns, to bring down its stake from 32% to 24%.

Haleon PLC (LSE:HLN, NYSE:HLN) said Pfizer Inc (NYSE:PFE, ETR:PFE) had sold a larger than expected amount of its shares overnight, scooping roughly £2.4 billion compared to the £2 billion expected

Pfizer faces challenges including declining COVID-19 sales and a looming patent cliff. However, the company's growth prospects look good.

Pfizer Inc (NYSE:PFE, ETR:PFE) has confirmed it will sell a large chunk of its stake in Haleon PLC (LSE:HLN, NYSE:HLN), raising over £2 billion (US$2.55bn). Haleon, a former consumer health joint ve

Consumer healthcare giant Haleon said on Monday that Pfizer will sell about 630 million of its shares in the company, reducing the US drugmaker's stake to about 24%.

Pfizer's stock has dropped over the last year+ due to declines in revenue and profit from Covid-related products. The company's non-Covid products have shown growth, indicating potential for continued

Alibaba should benefit from a strong AI tailwind. Enterprise Products Partners has a key advantage in delivering exceptional total returns.

Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.

Now might be a great time for investors to consider investing in precision medicine stocks. For those who don't know, precision medicine is an approach to disease treatment and prevention that tailors